Trial · NCT01443130
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Placental Malaria Infection Based on Histology | At delivery: Approximately 12-36 weeks after enrollment | The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue. |
| Secondary | Incidence of Placental Malaria by Placental Impression Smear | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results. |
| Secondary | Incidence of Maternal Anemia (Hemoglobin < 10 Grams/Deciliter) | From enrollment until delivery, approximately 12-36 weeks | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL). |
| Secondary | Incidence of Maternal Severe Anemia (Hemoglobin < 7gm/dl) | From enrollment until delivery, approximately 12-36 weeks | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl. |
| Secondary | Incidence of Stillbirth | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation. |
| Secondary | Incidence of Miscarriage | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation. |
| Secondary | Incidence of Preterm Delivery | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage. |
| Secondary | Infant Mortality Rate to 14 Weeks of Age | For 14 weeks after delivery. | Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery. |
| Secondary | Incidence of Low Birth Weight (LBW) (Birthweight < 2500 Grams) | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams. |
| Secondary | Incidence of Intrauterine Growth Restriction (IUGR) | At delivery: Approximately 12-36 weeks after enrollment | Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar. |
| Secondary | Incidence of Active Placental Malaria Infection | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR). |
| Secondary | Incidence of Malaria Infection, All Species. | Enrollment to delivery (approximately 12-36 weeks) | Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects. |
| Secondary | Incidence of Clinical Malaria, All Species | Enrollment to delivery (approximately 12-36 weeks) | Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness. |
| Secondary | Incidence of Infection in the Fetal Circulation | At delivery: Approximately 12-36 weeks after enrollment | Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01443130/registered